Zimislecel for treating type 1 diabetes

Zimislescel is currently in clinical development for adults with type 1 diabetes (T1D) with impaired hypoglycaemic awareness (reduced ability to recognise or perceive the onset of low blood glucose levels) and severe hypoglycaemia (low blood sugar). T1D is a chronic condition where the pancreas makes little or no insulin. Insulin is a hormone the body uses to allow sugar (glucose) to enter cells to produce energy. Symptoms of T1D include thirst, weight loss and frequent need to use the toilet. There are currently no cures for T1D, and the treatment options are limited to daily insulin injections which can hinder adherence to treatment and be a burden to individuals.